GlassScriptPhysician profile
Connie K Nguyen
NPI 1851471023
$20,968.60
in general payments reported to CMS, 2019-2025
61 companies · $4,380 in 2025
The $4,380 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,725 · 2020: $1,790 · 2021: $2,502 · 2022: $1,618 · 2023: $2,897 · 2024: $5,057 · 2025: $4,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $90.00 · Travel and Lodging: $10.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,234.03 |
| Education | $90.00 |
| Travel and Lodging | $10.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,013.22 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $2,128.71 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $2,065.99 | 2019-2025 | |
| Gilead Sciences, INC. | $1,496.97 | 2019-2025 | Vemlidy |
| Amarin Pharma, INC. | $1,460.94 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,216.53 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $865.78 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $759.59 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $697.45 | 2019-2025 | Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $575.57 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $525.49 | 2019-2024 | Veozah |
| Nestle Healthcare Nutrition INC. | $483.22 | 2020-2023 | |
| Pfizer INC. | $430.96 | 2019-2025 | |
| Dexcom, INC. | $374.28 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $365.63 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connie Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.